Hanmi Pharm Co Ltd
KRX:128940

Watchlist Manager
Hanmi Pharm Co Ltd Logo
Hanmi Pharm Co Ltd
KRX:128940
Watchlist
Price: 265 000 KRW -0.56%
Market Cap: 3.4T KRW
Have any thoughts about
Hanmi Pharm Co Ltd?
Write Note

Hanmi Pharm Co Ltd
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Hanmi Pharm Co Ltd
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Hanmi Pharm Co Ltd
KRX:128940
Cash from Operating Activities
â‚©222.9B
CAGR 3-Years
-1%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Yuhan Corp
KRX:000100
Cash from Operating Activities
â‚©59.7B
CAGR 3-Years
-2%
CAGR 5-Years
-4%
CAGR 10-Years
-3%
SK Biopharmaceuticals Co Ltd
KRX:326030
Cash from Operating Activities
-â‚©94.2B
CAGR 3-Years
24%
CAGR 5-Years
8%
CAGR 10-Years
N/A
Hanmi Science Co Ltd
KRX:008930
Cash from Operating Activities
â‚©42.3B
CAGR 3-Years
44%
CAGR 5-Years
25%
CAGR 10-Years
26%
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Cash from Operating Activities
â‚©38.4B
CAGR 3-Years
N/A
CAGR 5-Years
3%
CAGR 10-Years
9%
C
Celltrion Pharm Inc
KOSDAQ:068760
Cash from Operating Activities
â‚©55.9B
CAGR 3-Years
-10%
CAGR 5-Years
12%
CAGR 10-Years
N/A
No Stocks Found

Hanmi Pharm Co Ltd
Glance View

Market Cap
3.4T KRW
Industry
Pharmaceuticals

Hanmi Pharm Co., Ltd. is a remarkable player in the pharmaceutical industry hailing from South Korea, a country renowned for its technological and medical advancements. The company's journey began in 1973, and it has since carved out a substantial niche within the pharma sector by focusing on innovative research and development. Hanmi Pharm has been particularly recognized for its strong pipeline in pharmaceuticals addressing diabetes, oncology, and autoimmune diseases. It leverages its cutting-edge proprietary technology platforms such as LAPSCOVERY, which is dedicated to creating long-acting biologics, and Quantum Project, focused on novel small molecule drugs. These platforms are pivotal to Hanmi's strategy, enabling it not only to excel in creating new drugs but also to foster partnerships and licensing deals on a global scale, which constitute a significant revenue stream for the company. Beyond innovation, Hanmi Pharm has diversified its business operations across various sectors of pharmaceuticals including finished goods, active pharmaceutical ingredients (APIs), and over-the-counter (OTC) products. The company's revenue model is multifaceted and robust; it generates income by selling its pharmaceuticals in domestic and international markets and taps into significant contract manufacturing opportunities. Additionally, Hanmi Pharm has managed to establish strategic alliances with global pharmaceutical giants, resulting in lucrative licensing agreements. These collaborations allow Hanmi to not only broaden its distribution channels but also enhance its R&D capabilities by synergizing with the technological prowess of its partners. Through these multifarious routes, Hanmi Pharm has built a complex, enduring, and well-oiled machine that propels its financial growth and sustains its competitive edge within the industry.

Intrinsic Value
375 064.4 KRW
Undervaluation 29%
Intrinsic Value
Price

See Also

What is Hanmi Pharm Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
222.9B KRW

Based on the financial report for Sep 30, 2024, Hanmi Pharm Co Ltd's Cash from Operating Activities amounts to 222.9B KRW.

What is Hanmi Pharm Co Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
34%

Over the last year, the Cash from Operating Activities growth was 67%. The average annual Cash from Operating Activities growth rates for Hanmi Pharm Co Ltd have been -1% over the past three years , 34% over the past five years .

Back to Top